# Medical safety and appropriate use > **Research/history use only.** This database is not for diagnosis, not for > treatment, and not for self-treatment. It provides no prescriptions, dosing > instructions, product selection, or individualized guidance. It offers **no individualized guidance**. Historical use is not evidence of efficacy. A phrase such as `腎氣丸主之` says what one historical witness records; it does not establish a modern diagnosis, safe formulation, dose, composition, or clinical effect. Case reports do not establish efficacy: improvement can reflect co-treatment, selection/reporting bias, natural history, measurement error, or coincidence. Trials and systematic reviews retain their design and limitations and are not converted into advice. ## Do not use records as prescriptions Do not infer ingredients, preparation, route, dose, duration, substitutions, or cross-language formula identity when a source does not state them. Ancient, modern, and local terms are not identical. A historical term mapping is only a term-level, explicitly nonidentity research link and is never a diagnosis. Do not start, stop, replace, combine, or delay medical care because of this dataset. Conventional medicines, surgery, chemotherapy, radiotherapy, targeted therapy, dialysis, rehabilitation, acupuncture, supplements, and traditional products may interact or confound outcomes. Co-treatment fields report what a source said; they do not allocate causality. Product identity, processing, contamination, adulteration, and dose can materially change risk. The formula detail fields added for historical study—indication, treatment principle, provenance, modifications, cautions, ingredients, and source-era doses—exist so a reader can audit what the text says. They are not dose conversions, modern product specifications, or instructions for use. External links may point to a different edition, later formula monograph, library holding, or regulatory page; the database labels that role and does not infer identity. ## High-risk materials and authority alerts The release includes exact official safety-source models for high-risk materials: - UK Medicines and Healthcare products Regulatory Agency (MHRA), *Banned and restricted herbal ingredients*, exact Aconitum/Aconite table row and its jurisdiction-specific prescription-only restriction conditions. - US Food and Drug Administration, Import Alert 54-10, exact named alert section for listed products/materials. - Hong Kong Chinese Medicine Regulatory Office, official heavy-metal/adulteration safety material at its named official location. The source model is: one `regulatory_document` source + exact `source_locations` row + `safety_alerts` statement + `intervention_safety` link to the named intervention/ingredient. The record retains authority, date/access state, jurisdiction, location, and workflow status. It does not generalize one regulator's wording to every jurisdiction or product. Aconitum/aconite and other high-risk herbs can be dangerous; database presence is not a reason to use them. Materials associated with aristolochic acids, heavy metals, contamination, adulteration, organ toxicity, or narrow safety margins require authoritative product-specific and jurisdiction-specific review. A missing alert does not prove safety, and an authority alert does not prove that every similarly named local product is chemically identical. ## Interactions, adverse events, and failure evidence Interaction risk can involve prescription medicines, anticoagulants, immunosuppressants, cancer therapy, diabetes or blood-pressure medicines, anesthesia, kidney/liver impairment, pregnancy, allergies, and multiple products. This list is illustrative, not a personalized interaction screen. Consult a qualified clinician and pharmacist who can review the actual product, medicines, conditions, laboratory data, and local regulations. The database deliberately retains `unfavorable`, `mixed`, `no_clear_difference`, and `indeterminate` claims; adverse-event outcomes; reported nonresponse/failure; treatment discontinuation; and absent follow-up. “No adverse event reported” is not the same as demonstrated safety. Abstract-only sources may omit harms, dose, co-treatment, dropouts, or methods. Unreviewed translation and OCR/full-text limitations remain warnings rather than being silently resolved. ## When to seek help For urgent or severe symptoms—such as breathing difficulty, loss of consciousness, seizure, severe allergic reaction, chest pain, uncontrolled bleeding, marked confusion, poisoning concern, or rapidly worsening illness—use local emergency services or a poison-control service immediately. For nonurgent questions, bring the exact product label, ingredient list, source, and current medication list to a licensed clinician or pharmacist. Do not wait for database research when urgent care may be needed. This guidance is general and non-prescriptive. The project cannot assess an individual's diagnosis, product quality, interaction risk, dose, or suitability. ## Privacy and reporting Do not attempt to identify people from case labels, initials, dates, or clinical details. Ordinary living names are masked in the research export; source-faithful names require a located qualified disclosure and are suppressed for sensitive records. Public availability is not permission for contact, profiling, or redistribution outside applicable law and source terms. Corrections, privacy concerns, unsafe-source discoveries, and withdrawal requests should cite the source ID and exact location. Until resolved, disputed or withdrawn status must remain visible; material with blockers is excluded rather than presented as validated clinical guidance. ## Current release limitations Release `0.5.0` (2026-08-30, `Asia/Tokyo`) validates with 513 nonblocking warnings and 0 blockers: 130 missing outcome timepoints, 191 full-text unavailable flags, 187 unreviewed translations, and 5 unclear combination-treatment flags. Only 3 sources are reviewed, 264 are extracted, and 0 are publishable. A manual-release-check verifies traceability; it does not certify efficacy, safety, translation accuracy, or publication readiness.